Display options
Cite
Benedetti E, Galzio R, D'Angelo B, et al. PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors. PPAR Res. 2010;2010:427401doi: 10.1155/2010/427401.
Benedetti, E., Galzio, R., D'Angelo, B., Cerù, M. P., & Cimini, A. (2010). PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors. PPAR research, 2010427401. https://doi.org/10.1155/2010/427401
Benedetti, Elisabetta, et al. "PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors." PPAR research vol. 2010 (2010): 427401. doi: https://doi.org/10.1155/2010/427401
Benedetti E, Galzio R, D'Angelo B, Cerù MP, Cimini A. PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors. PPAR Res. 2010;2010:427401. doi: 10.1155/2010/427401. Epub 2010 Mar 17. PMID: 20339586; PMCID: PMC2841252.
Copy Download .nbib Format: NLM
Share it on

PPAR Res. 2010;2010:427401. doi: 10.1155/2010/427401. Epub 2010 Mar 17.

PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors.

PPAR research

Elisabetta Benedetti, Renato Galzio, Barbara D'Angelo, Maria Paola Cerù, Annamaria Cimini

Affiliations

  1. Department of Basic and Applied Biology, University of L'Aquila, 67100 L'Aquila, Italy.

PMID: 20339586 PMCID: PMC2841252 DOI: 10.1155/2010/427401

Abstract

Neuroepithelial tumors represent a heterogeneous class of human tumors including benignant and malignant tumors. The incidence of central nervous system neoplasms ranges from 3.8 to 5.1 cases per 100,000 in the population. Among malignant neuroepithelial tumors, with regard to PPAR ligands, the most extensively studied were tumors of astrocytic origin and neuroblastoma. PPARs are expressed in developing and adult neuroepithelial cells, even if with different localization and relative abundance. The majority of malignant neuroepithelial tumors have poor prognosis and do not respond to conventional therapeutic protocols, therefore, new therapeutic approaches are needed. Natural and synthetic PPAR ligands may represent a starting point for the formulation of new therapeutic approaches to be used as coadjuvants to the standard therapeutic protocols. This review will focus on the major studies dealing with PPAR expression in gliomas and neuroblastoma and the therapeutic implications of using PPAR agonists for the treatment of these neoplasms.

References

  1. J Clin Invest. 1999 Jul;104(2):155-62 - PubMed
  2. Glia. 2001 Mar 1;33(3):191-204 - PubMed
  3. Annu Rev Med. 2002;53:409-35 - PubMed
  4. Apoptosis. 2006 Sep;11(9):1503-12 - PubMed
  5. Clin Exp Pharmacol Physiol. 2006 Dec;33(12):1134-7 - PubMed
  6. Cancer Res. 1973 Nov;33(11):2643-52 - PubMed
  7. Biochem J. 2004 Aug 15;382(Pt 1):83-91 - PubMed
  8. J Neurocytol. 2001 Jan;30(1):21-33 - PubMed
  9. Int J Biochem Cell Biol. 2007;39(11):2093-106 - PubMed
  10. Clin Cancer Res. 2001 Jan;7(1):98-104 - PubMed
  11. Mol Cell Biol. 2000 Jul;20(14):5119-28 - PubMed
  12. J Natl Cancer Inst. 1982 Apr;68(4):589-96 - PubMed
  13. PPAR Res. 2007;2007:48242 - PubMed
  14. Annu Rev Cell Dev Biol. 1996;12:335-63 - PubMed
  15. Endocrinology. 2001 Oct;142(10):4195-202 - PubMed
  16. J Chem Neuroanat. 2003 Jan;25(1):29-38 - PubMed
  17. Nat Med. 1998 Sep;4(9):1046-52 - PubMed
  18. Oncol Res. 2004;14(7-8):345-54 - PubMed
  19. Endocrinology. 1998 Jun;139(6):2748-54 - PubMed
  20. Curr Opin Oncol. 2003 May;15(3):197-203 - PubMed
  21. J Pharmacol Exp Ther. 2005 May;313(2):806-13 - PubMed
  22. Science. 1984 Jun 8;224(4653):1121-4 - PubMed
  23. Mol Cell Biol. 2002 Jul;22(14):5114-27 - PubMed
  24. Int J Oncol. 2002 Nov;21(5):1141-50 - PubMed
  25. Toxicology. 2005 Sep 15;213(1-2):157-68 - PubMed
  26. Cell. 1992 Mar 6;68(5):879-87 - PubMed
  27. Bull Cancer. 2002 Jan;89(1):23-8 - PubMed
  28. Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2340-5 - PubMed
  29. J Clin Oncol. 2006 Mar 10;24(8):1253-65 - PubMed
  30. J Neurosci. 2000 Sep 15;20(18):6862-7 - PubMed
  31. Curr Opin Lipidol. 2003 Apr;14(2):129-35 - PubMed
  32. Cancer Res. 1998 Aug 1;58(15):3344-52 - PubMed
  33. J Cell Physiol. 2008 Oct;217(1):93-102 - PubMed
  34. Neuroscience. 2005;131(3):577-87 - PubMed
  35. Biochim Biophys Acta. 2000 May 1;1474(3):397-409 - PubMed
  36. J Biol Chem. 1999 Dec 10;274(50):35881-8 - PubMed
  37. Mutat Res. 2000 Mar 17;448(2):121-38 - PubMed
  38. J Neurocytol. 2001 Aug;30(8):671-83 - PubMed
  39. J Neurosci Res. 2000 Jul 1;61(1):67-74 - PubMed
  40. Prog Lipid Res. 2006 Mar;45(2):120-59 - PubMed
  41. Nature. 1998 Sep 10;395(6698):137-43 - PubMed
  42. J Biol Chem. 2004 Mar 5;279(10):8976-85 - PubMed
  43. Int J Dev Biol. 2000 Aug;44(5):429-42 - PubMed
  44. Br J Cancer. 2006 Oct 9;95(7):879-88 - PubMed
  45. Int J Oncol. 2004 Aug;25(2):493-502 - PubMed
  46. J Cell Physiol. 2007 Jun;211(3):837-47 - PubMed
  47. Int J Cancer. 1995 Aug 9;62(4):386-92 - PubMed
  48. Mol Pharmacol. 2006 Nov;70(5):1524-33 - PubMed
  49. J Neurochem. 2002 Jun;81(5):1052-60 - PubMed
  50. Br J Cancer. 2000 Nov;83(10):1394-400 - PubMed
  51. N Engl J Med. 1985 Oct 31;313(18):1111-6 - PubMed
  52. Cancer Res. 2000 Feb 15;60(4):1129-38 - PubMed
  53. Neoplasma. 2005;52(2):126-36 - PubMed
  54. Int J Cancer. 2005 Dec 20;117(6):923-33 - PubMed
  55. Endocrinology. 1996 Jan;137(1):354-66 - PubMed
  56. Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):235-46 - PubMed
  57. Acta Pharmacol Sin. 2009 Jul;30(7):935-46 - PubMed
  58. Nat Med. 1999 Feb;5(2):157-63 - PubMed
  59. Int J Dev Biol. 2002 Jan;46(1):105-14 - PubMed
  60. Neurochem Res. 2006 Nov;31(11):1305-16 - PubMed
  61. J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 - PubMed
  62. Lancet Oncol. 2004 Jul;5(7):419-29 - PubMed
  63. J Neurochem. 2003 Nov;87(3):742-51 - PubMed
  64. Biochem Soc Trans. 2004 Nov;32(Pt 5):840-2 - PubMed
  65. Mol Cancer Ther. 2007 Jun;6(6):1745-54 - PubMed
  66. J Immunol. 2004 Oct 15;173(8):5196-208 - PubMed
  67. Mol Cell. 1998 Feb;1(3):465-70 - PubMed
  68. J Nutr. 1999 Feb;129(2S Suppl):575S-580S - PubMed
  69. J Cell Physiol. 1992 Sep;152(3):536-44 - PubMed
  70. Nature. 1990 Oct 18;347(6294):645-50 - PubMed
  71. Nature. 2000 Jan 6;403(6765):103-8 - PubMed
  72. Med Pediatr Oncol. 2001 Jan;36(1):37-41 - PubMed
  73. Cancer Res. 2000 Oct 1;60(19):5558-64 - PubMed
  74. Gastroenterology. 1998 Nov;115(5):1049-55 - PubMed
  75. Neuroscience. 2005;130(2):325-37 - PubMed
  76. J Med Chem. 2000 Feb 24;43(4):527-50 - PubMed
  77. Int J Cancer. 1981 Nov 15;28(5):583-9 - PubMed
  78. Neuropathology. 2000 Sep;20(3):161-9 - PubMed
  79. J Neurochem. 1998 Apr;70(4):1366-75 - PubMed
  80. J Biol Chem. 2005 May 13;280(19):18667-82 - PubMed
  81. Neurosci Lett. 2007 Apr 24;417(1):72-7 - PubMed
  82. Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237-41 - PubMed
  83. Cell Growth Differ. 1996 Jun;7(6):775-85 - PubMed
  84. Expert Opin Investig Drugs. 2006 Sep;15(9):1039-49 - PubMed
  85. Biochim Biophys Acta. 2007 Aug;1771(8):1031-45 - PubMed
  86. Front Biosci. 2003 May 01;8:d577-88 - PubMed
  87. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 - PubMed
  88. Brain Res. 2003 Jun 13;975(1-2):10-21 - PubMed
  89. EXS. 2000;89:141-51 - PubMed
  90. J Biol Chem. 2005 Apr 8;280(14):14145-53 - PubMed
  91. Oncogene. 2005 Apr 14;24(16):2684-94 - PubMed
  92. Stem Cell Rev. 2008 Dec;4(4):293-303 - PubMed
  93. Neuroscience. 2004;123(1):131-45 - PubMed
  94. Curr Opin Oncol. 2001 May;13(3):160-6 - PubMed
  95. Brain Pathol. 1999 Jul;9(3):469-79 - PubMed
  96. J Biol Chem. 2004 Jun 4;279(23):23882-91 - PubMed
  97. Carcinogenesis. 2001 Nov;22(11):1747-55 - PubMed
  98. Neoplasia. 1999 Oct;1(4):330-9 - PubMed
  99. Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2613-8 - PubMed
  100. J Neurosci Res. 1998 Mar 1;51(5):563-73 - PubMed

Publication Types